Clinical Trial Search

Primary: Safety of Intravitreal Aflibercept Injection — 0; 0 adverse events

Primary: Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement. — 139.3; 135.9; 51.8; 172.3 microns

Primary: Complete Resolution of Subretinal Fluid — 0 participants

Primary: Change in Visual Acuity at Month 3 Compared to Baseline. — 0 ETDRS letters

Primary: Number of Participants That Achieved Complete Resolution of Subretinal Fluid on OCT Without Rescue Treatment — 16; 2 participants

Primary: Total Number of Severe Ocular Adverse Events Related to the Investigational Product — 0 Adverse Events

Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR

Primary: Multifocal Electroretinogram Amplitudes — 28.4; 32.2; 29.7; 36.1 microvolts

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly

Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events — 8; 9; 0; 0 Participants

Primary: Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline — 0 ETDRS letters

Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters

Primary: Total Number of Times a Subject Qualifies to be Administered IVT Aflibercept in Each Arm — 18; 7; 3; 12 Participants

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants

Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters

Primary: The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit — 5…

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…

Primary: Mean Change From Baseline in Best Corrected Visual Acuity Letter Score — 11.4; 13.8 letters — p=0.288

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye — 8.3; 5.1 Letters — p=<0.001

Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants

Primary: Mean Central Macular Thickness (CMT) on Spectral Domain OCT (SDOCT) at 12 Months — 413.4 Microns

Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05